These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20463947)

  • 1. Impact of bronchodilator therapy on exercise tolerance in COPD.
    Aguilaniu B
    Int J Chron Obstruct Pulmon Dis; 2010 Apr; 5():57-71. PubMed ID: 20463947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and exercise tolerance in stable COPD patients treated with long-acting bronchodilators.
    Kitaguchi Y; Fujimoto K; Komatsu Y; Hanaoka M; Honda T; Kubo K
    Respir Med; 2013 Mar; 107(3):394-400. PubMed ID: 23245993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD.
    Liesker JJ; Wijkstra PJ; Ten Hacken NH; Koëter GH; Postma DS; Kerstjens HA
    Chest; 2002 Feb; 121(2):597-608. PubMed ID: 11834677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients.
    Mroz RM; Minarowski L; Chyczewska E
    Adv Exp Med Biol; 2013; 756():23-8. PubMed ID: 22836615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function.
    Cooper CB
    Am J Med; 2006 Oct; 119(10 Suppl 1):21-31. PubMed ID: 16996896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis.
    Di Marco F; Sotgiu G; Santus P; O'Donnell DE; Beeh KM; Dore S; Roggi MA; Giuliani L; Blasi F; Centanni S
    Respir Res; 2018 Jan; 19(1):18. PubMed ID: 29368604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)].
    Szmidt M
    Pneumonol Alergol Pol; 2012; 80(3):255-62. PubMed ID: 22562275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bronchodilators reduce air-trapping in COPD patients].
    Welte T
    Med Klin (Munich); 2005 Oct; 100 Suppl 1():9-11. PubMed ID: 16422212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study Design of VESUTO
    Ichinose M; Minakata Y; Motegi T; Ueki J; Seki T; Anzai T; Takizawa A; Grönke L; Hirata K
    Adv Ther; 2017 Jul; 34(7):1622-1635. PubMed ID: 28537001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators.
    Halpin DM; Kaplan AG; Russell RK
    Respir Med; 2017 Jul; 128():28-41. PubMed ID: 28610667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA; Donohue JF
    Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease.
    Sethi S; Cote C
    Curr Clin Pharmacol; 2011 Feb; 6(1):48-61. PubMed ID: 21235463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
    Beeh KM; Beier J
    Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological treatment of stable chronic obstructive pulmonary disease].
    Allain YM; Giraud F; Huchon G; Roche N
    Presse Med; 2009 Mar; 38(3):432-44. PubMed ID: 19171453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance.
    Ambrosino N; Foglio K; Balzano G; Paggiaro PL; Lessi P; Kesten S;
    Int J Chron Obstruct Pulmon Dis; 2008; 3(4):771-80. PubMed ID: 19281092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redefining treatment in COPD: new directions in bronchodilator therapy.
    Lipson DA
    Treat Respir Med; 2004; 3(2):89-95. PubMed ID: 15182210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bronchodilators in COPD: latest recommendations, recent data and perspectives].
    Roche N
    Presse Med; 2004 Jan; 33(2):111-8. PubMed ID: 15026706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When?
    Mathioudakis AG; Vestbo J; Singh D
    Clin Chest Med; 2020 Sep; 41(3):463-474. PubMed ID: 32800199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
    Chen AM; Bollmeier SG; Finnegan PM
    Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.